Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$35.24 USD

35.24
783,779

-0.32 (-0.90%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $35.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TNDM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Tandem Diabetes Care, Inc. [TNDM]

Reports for Purchase

Showing records 161 - 180 ( 239 total )

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 161

12/17/2015

Industry Report

Pages: 7

Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 162

10/30/2015

Company Report

Pages: 9

Impressive Q3 Results, Price Target to $14.75, Reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 163

10/30/2015

Company Report

Pages: 9

The Calm Before The Storm; Expecting Sales To Significantly Accelerate in 4Q and Beyond; Reiterate

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 164

10/29/2015

Company Report

Pages: 7

Feltl Insulin Pump Project: Historical survey of -5,700 users, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 165

10/29/2015

Company Report

Pages: 7

Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 166

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 167

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 168

09/10/2015

Company Report

Pages: 7

FDA approves t:slim-G4 combo device, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 169

09/09/2015

Daily Note

Pages: 5

T:slim G4 Receives FDA Approval; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 170

09/09/2015

Company Report

Pages: 7

Conference Call Takeaways Following t:slim G4 Approval; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 171

08/11/2015

Industry Report

Pages: 17

Medical Devices - Key Takeaways from the Wedbush PacGrow Healthcare Conference

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 172

08/11/2015

Daily Note

Pages: 17

Key Takeaways from the Wedbush PacGrow Healthcare Conference

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 173

07/31/2015

Company Report

Pages: 8

Q2 beats, t:flex guidance raised, pipeline on track, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 174

07/30/2015

Company Report

Pages: 8

Insulin Pump Project: Historical survey of ~5,500 users, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 175

07/30/2015

Company Report

Pages: 8

Rapid Adoption of Tandem''s Insulin Pump Continues Unfazed by Competition; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 176

07/17/2015

Daily Note

Pages: 41

Medical Devices - 2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 177

07/17/2015

Daily Note

Pages: 41

2Q15 Preview: MedTech Underlying Fundamentals Healthy and Outlook for 2H15 Remains Positive

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 178

05/04/2015

Company Report

Pages: 9

Q1 slightly ahead, guidance reiterated, pipeline updates, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 179

05/01/2015

Company Report

Pages: 7

Solid 1Q15 Results Driven By Robust Demand For t:slim Pumps; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 180

04/30/2015

Company Report

Pages: 8

Q4 ahead of estimates, pipeline updates, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party